Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Liver Tumors
What is your (institutional) approach to treatment options (ex: SBRT, chemotherapy) in liver transplant protocols for control of unresectable hepatic colorectal metastases while awaiting transplant?
Related Questions
How does the identification of a hepatic adenoma in a male patient affect your management and evaluation?
What is your evaluation approach for a new patient referral for an incidentally found liver lesion?
How does the use of checkpoint inhibitors for treatment of HCC impact timing of liver transplant and subsequent immunosuppression?
How has the GALAD score affected your practice for HCC screening?
How do you foresee the integration of artificial intelligence in the management and evaluation of patients with liver lesions/tumors?
How do you counsel patients experiencing symptoms/complications of menopause who desire use of HRT if they have a history of known hepatic adenomas?
When would you plan to biopsy a hepatic adenoma to see if it has high risk features/mutations?
What clinical features would raise your suspicion for IgG-4 related disease?
How does your surveillance and management approach differ between intra-hepatic and extra-hepatic cholangiocarcinoma?
How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?
